Deal to acquire Covis is expected to expand Azurity’s portfolio across multiple complex dosage forms and key therapeutics ...

A panel discussion at the Global Life Science Partnering and Investor Conference discusses various strategies and trends in ...

New real-world and implementation study data highlight the efficacy of ViiV’s long-acting injectables for HIV prevention and ...

Dr. Dina Radenkovic, CEO of Gameto, discusses the key considerations for bringing iPSC-based fertility treatments to market from a regulatory and manufacturing perspective.

Artiva Biotherapeutics' CEO Fred Aslan, MD, explains the strategic advantages of pursuing both a company-sponsored trial and an investigator-initiated trial simultaneously.

Immunotherapy pioneer Mark Frohlich, MD, CEO of Indapta Therapeutics, discusses the promise of harnessing natural killer cells to reshape treatment for cancer and autoimmune disease.

John Arena is interim president of global pharma services at Cencora, managing a team that offers a broad range of solutions ...

Dr. Dina Radenkovic, CEO of Gameto, discusses the use of iPSCs in fertility treatments, the most significant scientific hurdles they've encountered in developing and scaling these therapies ...

Jonathon Whitton, AuD, PhD, VP, auditory global program head, Regeneron, discusses regulatory challenges for DB-OTO, Regeneron’s AAV-based gene therapy for hearing loss.

CordenPharma, a CDMO focused on peptides and peptide-based therapeutics, announced a partnership with Viking Therapeutics.

In a perfect world, every emerging biopharma company would have a clear short- and long-term vision leading up to launch.

A Harvard Business School Healthcare Alumni Association Q&A with Elaina Shekhter, EPAM’s Chief Marketing & Strategy Officer.